VitalScientific

Van Rensselaerweg 4
Spankeren,  Gelderland  6956AV

Netherlands
https://vitalscientific.com

• Booth: 5125

 Press Releases

• Lithium Reagent - Single Liquid Stable (Mar 18, 2025)
  
  PRODUCT NEWS
  Unlock the potential of Lithium testing
  Lithium is the most widely used and recommended standard long-term treatment for bipolar disorder, and one of the most consistently effective medicines in psychiatry. ^(1,2,3,4,5)
  The prevalence of bipolar disorder and growing awareness of therapeutic drug monitoring has driven significant growth in lithium testing. However, some of the current routine IVD Lithium testing methods encounter challenges. Atomic Absorption spectrophotometry (AAS) is considered a cost-effective option but requires special equipment or sample splitting. Ion-selective electrode (ISE) is seen as expensive to maintain for low-volume tests (c/w Na/K/CL).
  Significant competitive advantages with new Lithium reagent*
  Our new Lithium reagent offers an attractive and cost-effective alternative to the prevailing assays on the market. This enhancement in cost-effectiveness benefits smaller to mid-sized laboratories that do not utilize large IVD platforms and reduces the associated costs of transitioning away from Lithium ISE.
  Expand your system test menu and availability of Lithium. For more information, please visit www.vitalscientific.com
  The VitalScientific Lithium reagent is a product of well-proven technology, carefully manufactured in our state-of-the-art, CE-IVDR and ISO 13485:2016 compliant facility in France, Europe.

  • Single Liquid stable reagent
  • Measuring Range 0.1 – 3.0 mmol/L
  • Method: Decreasing Endpoint
  • Sample type: Serum/ Plasma
  • Primary Wavelength: 505-520 nm
  • Secondary Wavelength :450-480 nm

  For consistent, accurate, and reliable results on VitalScientific’ s Selectra analyzers, Selectra System Reagents, Calibrators, and Controls are recommended.
  
  *Product availability may be subject to regulatory requirements. Please contact your local representative for more information.
  
  Lithium References

  1. Lithium: the gripping history of a psychiatric success story Nature 572, 584-585 (2019)
  2. National Institute for Health and Care Excellence. 2014. Bipolar disorder: assessment and management. [Clinical Guideline; CG185] https://wwwniceorguk/guidance/cg185
  3. Nederlof M, Kupka RW, Braam AM, Egberts A, Heerdink ER. Evaluation of clarity of presentation and applicability of monitoring instructions for patients using lithium in clinical practice guidelines for treatment of bipolar disorder. Bipolar Disord. 2018;20:708–20.
  4. Nikolova VL, Pattanaseri K, Hidalgo-Mazzei D, Taylor D, Young AH. Is lithium monitoring NICE? Lithium monitoring in a UK secondary care setting. J Psychopharmacol. 2018;32:408–15.
  5. Nolen WA, Licht RW, Young AH, Malhi GS, Tohen M, Vieta EK, et al. What is the optimal serum level for lithium in the maintenance treatment of bipolar disorder? A systematic review and recommendations from the ISBD/IGSLI task force on treatment with lithium. Bipolar Disord. 2019;21:394–409.
  6. International Bipolar Foundation (IBPF) https://ibpf.org/wp-content/uploads/2022/04/impact-report-22022.pdf
  7. Monitoring of patients treated with lithium for bipolar disorder: an international survey, Nederlof et al. Int J Bipolar Disord (2018) 6:12 https://doi.org/10.1186/s40345-018-0120-1
  8. Ng F, Mammen OK, Wilting I, Sachs GS, Ferrier IN, Cassidy F, et al.. The International Society for Bipolar Disorders (ISBD) consensus guidelines for the safety monitoring of bipolar disorder treatments. Bipolar Disord 2009; 11: 559- 595.

• Pseudocholinesterase - Ready to use Liquid Stable (Mar 19, 2025)

  What is Pseudocholinesterase deficiency?

  The primary role of Cholinesterase in Clinical Diagnostics is to detect or monitor an acquired or inherited pseudocholinesterase deficiency. Pseudocholinesterase deficiency is a condition that causes increased sensitivity to certain muscle relaxant drugs used during general anesthesia (choline esters). These drugs relax the muscles used for movement, including those used for breathing. Normally, the muscles are able to move again a few minutes after the drugs are given. People with Pseudocholinesterase deficiency may not be able to move or breathe on their own for a few hours after these drugs are given.(1)

  If pseudocholinesterase deficiency stays undetected it may lead to prolonged muscular paralysis after clinical anesthesia.

  Other conditions impacting serum Cholinesterase activity

  Other clinical conditions that may impact serum Cholinesterase activity are acute and chronic liver disease, inflammation, malnutrition, and Alzheimer’s disease. Also, exposure to pesticides containing organophosphates or any other deliberate or unintended exposure to organophosphates may affect Cholinesterase in serum. Organophosphates bind and inhibit cholinesterase activity affecting the peripheral and central nervous system.

  Choline esters

  Cholinesterase hydrolyses choline esters and there are two types: Acetylcholinesterase and Pseudocholinesterase

  They are distinguished from each other based on the preferred substrate: Acetylcholine or Butyrylcholine. Pseudocholinesterase is found predominantly in the liver but also in the pancreas, intestine, heart, and brain, and it’s present in serum/plasma. Acetylcholinesterase is found in red blood cells and nervous tissue.

  Methods for estimating Cholinesterase activity

  A number of methods utilizing a range of detection technologies have been developed for estimating serum/plasma Cholinesterase activity, however, many of these are not so well suited to routine use or require specialized equipment, which may not be readily available. The most common method used in routine clinical chemistry service laboratories is spectrometry, detecting thiocholine or other substrates (Ellman, Garry & Routh method or DGKC method).(2)

  What about VitalScientific Cholinesterase reagent?

  The VitalScientific Cholinesterase* reagent is available as a common kit for Selectra systems. The Cholinesterase reagents are ready-to-use liquid stable, with 8 weeks of onboard stability (Selectra Pro & Mach series). The method is based on the DGKC published method and provides significantly better onboard reagent and calibration stability compared with commercial reagents utilizing the Ellman method. The calibration is traceable to DGKC method using the ELICAL calibrators.

  VitalScientific Cholinesterase reagents have an ideal shelf life and combined with optimized packaging; it offers an economical option for low-volume testing.

  For more information: See Reagent Catalogue or contact us.

  1. https://rarediseases.info.nih.gov/diseases/7482/pseudocholinesterase-deficiency
  2. S. Chowdhary et al. / Clinica Chimica Acta 431 (2014) 66–76
  3. Photo by Anna Shvets: https://www.pexels.com/photo/anesthesia-mask-lying-in-an-operating-room-during-surgery-6291290/

  *Product availability may be subject to regulatory requirements. Please contact your local representative for more information.